Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:26 PM
Ignite Modification Date:
2025-12-24 @ 9:26 PM
NCT ID:
NCT07176832
Eligibility Criteria:
Inclusion Criteria
* Aged between 18 and 50 years (inclusive).
* Considered healthy after a comprehensive clinical assessment (medical history + complete physical exam).
* Body Mass Index (BMI) between 18 and 30 kg/m² (inclusive) and body weight ≥ 50 kg at screening.
* Normal blood pressure (BP) and heart rate (HR) after 10 minutes supine at screening : Systolic BP: 90-145 mmHg, Diastolic BP: 45-90 mmHg, HR: 40-90 bpm, Or values outside these ranges but judged not clinically significant (NCS) by the Investigator.
* Normal ECG at screening (10-min resting 12-lead ECG): PR interval: 110-210 ms, QRS interval : \< 120 ms, QTcF interval: ≤ 450 ms, No evidence of sinus node dysfunction, Or values outside these ranges but judged NCS by the Investigator.
* Laboratory parameters within normal ranges (hematology, biochemistry, urinalysis); slight deviations allowed if not clinically relevant per Investigator.
* Women of non-childbearing potential, or women of childbearing potential using at least one acceptable contraceptive method throughout the study and 1 month after last treatment.
* Female subjects of childbearing potential: negative pregnancy test (serum or urine) at screening and Day 0.
* Covered by Health Insurance System and/or compliant with National Law requirements for biomedical research.
* Able and willing to comply with study requirements.
* Written informed consent obtained.
Exclusion Criteria
* Unsuitable veins for repeated venipuncture.
* Relevant history/presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, psychiatric, systemic, or infectious disease.
* Evidence of any clinically significant acute or chronic disease.
* History of suicidal ideation or suicide attempt.
* Surgery (including clinical trial procedures) within 2 months before dosing.
* Blood donation within 2 months before dosing.
* History/presence of drug hypersensitivity, asthma, or allergy.
* Known hypersensitivity to study materials or related compounds.
* Inability/difficulty swallowing capsules.
* No possibility of emergency contact.
* Any drug intake (except paracetamol) within 4 weeks prior to dosing or \< 5 half-lives (whichever longer). Prohibited: carbamazepine, phenytoin, phenobarbital, CYP enzyme modulators.
* Use of herbal products affecting CYP enzymes within 2 weeks or \< 5 half-lives before dosing.
* Special diets (vegetarian, vegan, gluten-free).
* Vigorous exercise from 4 days before dosing until post-study assessments.
* Pregnant or breastfeeding women.
* Drug/alcohol abuse history, daily alcohol intake \> 4 drinks, or positive alcohol test.
* Excessive xanthine beverages (\> 5 cups/day).
* Nicotine use \> 5 cigarettes/day or inability to abstain 48h before and during study.
* Intake of grapefruit/Seville oranges/poppy seed or other CYP modulators 1 week before dosing and during study.
* Intake of methylxanthines (coffee, tea, cola, cocoa, mate, guarana, chocolate) or quinine (e.g., tonic water) from 48h before dosing and during study.
* Unable/unwilling to follow diet requirements (see protocol section 10.7).
* Positive test for HBsAg, HCV antibody, or HIV 1/2.
* Positive drug screen.
* Significant biological or clinical abnormalities judged incompatible with study.
* Participation in another interventional trial during exclusion period or investigational product within last 60 days or \< 5 half-lives.
* Under guardianship, curatorship, or deprived of liberty.
* Under Court protection.
* Would exceed €6000 compensation for biomedical research in last 12 months (including this study).
* Health status not allowing provision of informed consent.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT07176832
Study Brief:
Protocol Section:
NCT07176832